This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Extramedullary involvement (or extramedullary disease, EMD) in multiple myeloma (MM)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Extramedullary involvement (or extramedullary disease, EMD) in multiple myeloma

  • multiple myeloma (MM)
    • is a mature B-cell neoplasm defined by the presence of >=10% of clonal plasma cells (PCs) in the bone marrow (or plasmacytoma confirmed by biopsy) and by evidence of end-organ damage (hypercalcemia, renal insufficiency, anemia, bone lesions) caused by the PC disorder
      • PC proliferation is restricted to bone marrow in most patients with MM, a subset develops soft-tissue plasmacytomas, whereby clonal PCs escape and are found outside the bone marrow

  • extramedullary involvement (or extramedullary disease, EMD)
    • represents an aggressive form of multiple myeloma (MM), characterized by the ability of a clone and/or subclone to thrive and grow independent of the bone marrow microenvironment
    • defined by the presence of extraskeletal (i.e. soft tissue or visceral) clonal plasma cells infiltrates
      • can be present either at the time of initial diagnosis (primary EMD) or at the time of relapse (secondary EMD)
    • can be either:
      • a) tumor mass adjacent to bone and extending into soft tissues;
      • b) soft tissue or visceral tumor that is not connected to the bone; or
      • c) diffuse infiltration of organs by plasma cells without any obvious focal lesion
    • most common sites of EMD occurrence at diagnosis were skin/muscle (24%), pleura (12%), lymph nodes (10%), liver (9%), and CNS (6%) (1)
    • presence of soft-tissue plasmacytomas represents an aggressive form of MM, which can be found at the time of MM diagnosis or at relapse
    • study evidence (2)
      • found evidence of EMD in 24% (55 of 226) of evaluable relapsed MM patients
        • in 14% (32 of 226) of these patients, the lesions were not adjacent to bone and thus were classified as EMD-S (soft tissue), while EMD-B (bone) was documented in 10% (23 of 226) of cases
          • in the EMD-S group, the most common site of EMD was skin and subcutaneous tissue (69%), while extramedullary masses extending from vertebrae (78%) were most common in the EMD-B group.
      • patients with soft tissue-related extramedullary relapse had significantly poorer overall survival compared to bone-related extramedullary relapse patients
      • overall survival from diagnosis was as low as five months for soft tissue-related extramedullary relapse patients when compared to 12 months overall survival for bone-related extramedullary relapse

Reference:

  1. Blade J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, Rasche L, Rosiñol L, Usmani SZ, Zamagni E, Richardson P. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022 Mar 21;12(3):45. doi: 10.1038/s41408-022-00643-3. PMID: 35314675; PMCID: PMC8938478
  2. Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, Sandecka V, Adam Z, Krejci M, Kuglik P, Hajek R. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014 Feb;99(2):360-4. doi: 10.3324/haematol.2013.094409. Epub 2013 Sep 13. PMID: 24038024; PMCID: PMC3912968.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page